

A revolutionary leap forward
in the well-being of humanity
through real-time continuous
biomarker and drug monitoring

SPIDEN

Label-free biomarker sensing

Leveraging CMOS technology & photonic integration

Leo Grünstein, Jens Hofrichter, Spiden AG

November 15th, 2022

© SPIDEN AG 2022 – CONFIDENTIAL AND PROPRIETARY

Any use of this material without specific permission of Spiden is strictly prohibited

Our vision

In the future, our bodies and technology will become one. Continuous health monitoring through next generation wearables and implants will be the standard, allowing us to live longer, healthier lives.

The problem we solve

Continuous, simultaneous and label-free monitoring of multiple biomarkers and drugs in fluids, cells and tissue presents huge opportunities in pharma and medicine. Adoption, however, has been held back by the complexity and lack of robustness of current technology. We are changing that.

Our solution

We are a deep-tech start-up, combining a novel optical monitoring platform through integration of unique photonic sensors, light sources and fluidics, with state-of-the-art machine learning methods. This provides superior biochemical specificity and robustness in the most demanding use cases, removing the need for reagents or labels.

Our goal is to enter the wearables market through launching a Spiden wearable with non-invasive multi-biomarker/drug monitoring capabilities, starting with glucose

Wellness oriented glucose monitoring

Currently available CGM (continuous glucose monitoring) devices

Cost per year and person, USD/y



1'800
(athlete focused)



2'400
(diet focused)



2'400
(diet focused)

Medically oriented glucose monitoring



2'000
(revenue: 2.7bn)



3'500
(revenue: 1.7bn)



4'000
(revenue: 0.9bn)



All these products are minimally invasive and need to be changed every 1-2 weeks



Total addressable market, USD/y

- Health/diet optimizers: >300bn* (>170m on a diet in US/EU at every given moment, alone)
- Athletes: >7bn* (>4m endurance athletes in US/EU alone)

- Diabetes glucose monitoring: current market at >12bn, of which already 5bn are made up by minimally invasive CGM (continuous glucose monitoring) devices

USD >300bn in addressable market across wellness and medical
And this is glucose only ... imagine a multi-biomarker/drug monitoring device

*As a reference we take existing continuous glucose offerings which are at roughly USD 2000 per person and year

Our learnings of why transcutaneous glucose and multi-biomarker monitoring has not been achieved yet



Lack of understanding why it fails

This is why we follow a **stepwise development approach**



See next page

Lack of robustness across many people

This is why we developed a **proprietary integrated computational and measurement strategy** to handle the variability

Lack of specificity and breadth in spectroscopy


This is why we believe that using **multiple forms of spectroscopy** can provide important breadth capturing information necessary for achieving robustness

Lack of robustness to confounding analytes

This is why we further develop **ML/analytical methods** that are able to account for confounding analytes robustly

We believe that our integrated expertise, infrastructure and approach address these problems

We follow a **stepwise development strategy** with the objective to present data **proofing our transcutaneous glucose monitoring approach by H1'23**



Spiden built up the critical infrastructure and capabilities to develop these complex assets and products under one roof



ALL INFRASTRUCTURE IS UNDER ONE ROOF IN A STATE-OF-THE-ART 1800 SQM LABORATORY AND OFFICE SPACE IN PFÄFFIKON (SZ), SWITZERLAND

Biophotonics lab




- Multiple highly flexible spectroscopy setups
- Ability to run spectroscopy experiments at scale

Fluidics lab




- Methods & equipment enabling design of complex sample/spectroscopy interfaces as well as fluidic systems

Software & machine-learning infrastructure




- Integrated pipeline from lab to cloud-based data lake for processing and analysis
- Full-stack capabilities for AI-based products

Electronics engineering lab



- Proprietary detector chip platform with unique capabilities (high speed, high sensitivity)
- Lab infrastructure for design/characterization

System engineering lab



- System integration lab with testing capabilities
- Access to applicable standards & regulations

Biochemistry lab




- Biomedical laboratory on biosafety level 2, with high throughput gold standard testing capabilities
- >100 samples per hour preparation capacity

Focusing on a transcutaneous glucose monitoring wearable, we mainly **system-integrate**, and only selectively invest in **deep tech**

A wide range of **sophisticated technologies** are needed to create a transcutaneous glucose wearable product...

... and Spiden chooses the most **appropriate strategy** for fulfilling these needs from a **product company perspective**




	Develop	Partner	Source
ML toolchain		×	×
ML algorithms	×		×
Spectral database	×		×
Light sources		×	×
Light guides		×	×
Light detectors	×	×	
Photonics engine	×	×	
Filters & diffractive elements		×	×
Data processing			×
Power			×
Display			×
Packaging			×

Spiden created the required inhouse capabilities for system integration and laboratory (incl. data generation/gold standard measurements)

Spiden's CMOS detector specification (3rd generation)



Preliminary datasheet



Spiden's 3rd generation
CMOS detector IC

- Sensor available for 3rd parties
- Contact Spiden for samples

Characteristics	Value
Detector type	CMOS - SPADs
Detector manufacturer	Spiden's CMOS foundry partner
Cooling	No
Key specifications	• Lowest noise • Shortest integration time • Highest sensitivity
Applications	• Advanced Raman spectroscopy with fluorescence suppression • Fluorescence lifetime imaging
Chip size	3 mm x 5 mm
3-sides buttable	Yes
Pixel array	232 (c) x 56 (r)
Pixel size	20.3 x 35.8 μm
Active SPAD area (diameter)	9.3 μm
Wavelength range	350 - 950 nm
SPAD On/Off	Yes
SPADs downtime	> 15 ns
Temporal resolution	> 600 ps gate @ 20 ps steps (one independent gate per pixel)
Dark noise	300 counts/pix/s*
Readout noise	0
Conversion efficiency	>1.5 V / SPAD event

Characteristics	Value
Imaging mode of operation	• Pixel-by-pixel readout • 1 bit memory per gate per pixel • Frame rate: 25.2 kHz (39.7 μs per frame per gate)
Spectroscopy mode of operation	• All hit pixels per column are counted • Column-wise readout • 10 bit counter per gate per column • Frame rate: 143.7 kHz (6.96 μs per frame per gate) • Repetition rate: > 675 ns (inside same frame, per gate) • Max. repetitions per frame (per gate): 18
Data rate	332 Mbps (4 serial outputs @ 83 MHz)

*Typical value @ 25°C; decrease possible with added cooling

Spiden chips offer improved performance for both spectroscopy and imaging applications



	State-of-the-art SPAD*	Spiden ASIC	Spiden performance
SPAD PDP @ 900nm	< 5%	> 18%	Enhanced infrared sensitivity
Temporal resolution	> 30 ps	< 20 ps	High temporal resolution
Frame rate	6 Hz – 97.7 kHz	25 kHz – 1'000 kHz	High speed
Applications	2D / 3D imaging	2D / 3D imaging and (time-resolved) spectroscopy	Multimodality

PDP = Photon Detection Probability

*Chips based on the same base technology as Spiden chips

Technology and USPs

9


CONFIDENTIAL AND PROPRIETARY

Spiden CMOS detector technology allows for efficient fluorescence background suppression and improved SNR




Example setup


Sketch of experimental setup in Spiden laboratory



Commercial cooled CCD




Spiden CMOS detector



- Spiden uncooled proprietary detector was benchmarked against a scientific cooled CCD camera
- 10x reduction in fluorescence background during measurements of urea demonstrated


Spiden's CMOS detector technology allows for efficient fluorescence background suppression and thus improved SNR

Outlook: the journey towards system-level photonic integration of spectrometers



The **laser source** can be integrated to some extent, it needs to be made **cheap and small**


Example of a Raman spectrometer



The **detector** can be integrated with CCD / CMOS / SPAD (Charbon et al, SwissSpad2, etc.)

The **grating** can be integrated with AWG / CMZI DWDM / interference filter:

- Need flat top-response for process & alignment tolerances
- Low-loss for low-light applications (single photons)
- Ideally coherent interference like MZI




HOWEVER: FOR INTEGRATED BIOPHOTONICS SPECTROMETERS, SOME COMPONENTS ARE STILL MISSING (SEE NEXT PAGE)

Biophotonics needs **silicon nitride photonics platform** and ecosystem around it (e.g., fab access, test platforms, software, people)


Existing photonics platforms

R&D and small volume




*LioniX Triplex Platform
IMEC BioPIX, others...*

Large volume



Ligentec / X-Fab

Spiden's product needs following currently missing building blocks



*Towards an integrated
photonics spectrometer*

1

Coherent interferometers

High photon efficiency for low light operation: every photon counts - we cannot afford reflected light!

2

High spectral channel count per die

Large number of channels translates to high spectrometer resolution

3

Flat-top spectral pass bands

Account for laser jitter, alignment tolerances and temperature drift

4

Vertical coupling between photonics die and silicon detector chip

High efficiency, large alignment tolerances, low divergence

5

850 nm single-mode photonics platform

Water absorbs above 1400 nm, where silicon photonics works best

Many components are **still missing and yet to be developed**

We built a team with deep experience in entrepreneurship, MedTech product development and Spiden's science disciplines



Leo Grünstein
Founder & CEO



Bernd Wittner
Chief technology officer



Adler Perotte
Chief science & innovation officer



Daniel Thürig
VP operations & strategy



Öyünc Okyay
Co-founder & venture builder



Fabien Rebeaud
Director biomedical sciences



Emmanuel Delamarche
Senior manager microfluidics



Mattias Cattepoel
Manager system engineering



Jens Hofrichter
Lead system designer optics and photonics



Paolo Livi
Team lead electronics engineering



J.C. Blancon
Team lead biophotonics



Jaime Moreno Mateos
Team lead software & machine learning engineering



Elizabeth Canovic
Lead engineer biomedical initiatives

- Raised USD >600m (of which USD >25m for Spiden) and created 20+ ventures, of which most are successful
- Developed devices across a wide range of medical, photonic, and imaging use-cases including surgical microscope binoculars, genome sequencers, Raman spectrometers, silicon nanowire-based chemical sensor arrays, nerve-on-a-chip platforms
- Built and productionized machine learning and deep learning pipelines at scale across various industries
- Strong mix of academic, research, and industrial backgrounds including Harvard, MIT, Rice, ETH, CERN, IBM and McKinsey
- >300 papers published including many in Nature, Science, Physical Review, PLoS
- Diverse and complimentary team members from 14 countries and 5 continents

+ 30 additional full time team members across R&D, Science & Innovation and Strategy & Operations

Things to remember from today



- 1 Spiden's goal is a **non-invasive multi-biomarker/drug monitoring wearable** for wellness as well as medical applications, and our objective is to present data **proofing our transcutaneous glucose monitoring approach by H1'23** – we mainly system integrate, and only selectively invest in deep tech development such as our own light detector and our photonics engine
- 2 **Our proprietary light detector** supports time-gated Raman spectroscopy and fluorescence lifetime imaging (FLIM) at a small form factor without the need for cooling – *contact us, if you are interested*
- 3 Spiden is actively working towards integrated spectrometer systems **using photonic integrations** - the eco system needs to be developed further to meet the needs of **biophotonic systems operating around 850 nm and we are open for partnering** – *contact us, if you are interested*

Contact details Jens Hofrichter



Questions?
www.spiden.com